Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) EBITDA (2016 - 2020)

Historic EBITDA for Conmed (CNMD) over the last 11 years, with Q4 2020 value amounting to $135.5 million.

  • Conmed's EBITDA fell 455.08% to $135.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $460.3 million, marking a year-over-year decrease of 1227.6%. This contributed to the annual value of $59.6 million for FY2025, which is 5181.92% down from last year.
  • According to the latest figures from Q4 2020, Conmed's EBITDA is $135.5 million, which was down 455.08% from $133.7 million recorded in Q3 2020.
  • In the past 5 years, Conmed's EBITDA ranged from a high of $142.0 million in Q4 2019 and a low of $71.9 million during Q2 2020
  • Over the past 5 years, Conmed's median EBITDA value was $113.4 million (recorded in 2018), while the average stood at $114.7 million.
  • As far as peak fluctuations go, Conmed's EBITDA skyrocketed by 1761.23% in 2019, and later plummeted by 4517.19% in 2020.
  • Conmed's EBITDA (Quarter) stood at $107.0 million in 2016, then increased by 15.89% to $124.0 million in 2017, then grew by 7.02% to $132.7 million in 2018, then grew by 7.03% to $142.0 million in 2019, then decreased by 4.55% to $135.5 million in 2020.
  • Its last three reported values are $135.5 million in Q4 2020, $133.7 million for Q3 2020, and $71.9 million during Q2 2020.